MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why MBRX Stock slipped -0.29% Today — RQD Quant Desk Flash
$8.72 -0.29% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $8.70
Moleculin Biotech Inc. (MBRX) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • SELL / AVOID
Cap $9.2M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $8.70 (-0.24%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE-6.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MBRX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (43/100 Composite)
🔍 WHY MBRX SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (35% of score)
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 44.6 (NEUTRAL RANGE)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (23% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)
Capital intensity & 0% operating margin leave 16 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$8.84-36.7% Next Q
51
Q2 (-2Q)Grade D$5.60+16.1% Next Q
48
Q3 (-1Q)Grade D$6.50+34.2% Next Q
46
CurrentGrade D-$8.72-6.7% Hist 90D α
43
Trajectory: C- (51) → D- (43)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a MBRX Turnaround Squeeze
While MBRX currently carries a cautious 43/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($10.84) and Max Pain ($9.16) forces dealer call-delta covering toward $330.75.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $MBRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MBRX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why MBRX Stock slipped -0.29% Today — RQD Quant Desk Flash
Moleculin Biotech Inc. (MBRX) slipped -0.29% to $8.72, trading at 2% of its 52-week range ($3.22 – $315). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($3.22 – $315) with RSI-14 at 44.6 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $8.72 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live MBRX Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MBRX)
- ✓Walkthrough of MBRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
MBRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -82.97%⚡ TESTING RESISTANCE
2026-10-30O $8.80H $9.00L $7.90C $8.72VOL 31.7K
RES: $8.74SUP: $4.62SMA50: $10.84SMA200: $40.39
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
MBRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on MBRX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for MBRX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MBRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MBRX)
Health Care Rank #561 of 1016
⚔️ BFRG vs MBRX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (MBRX vs. BFRG, INM, PTN, CMMB)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Moleculin Biotech Inc. (MBRX) ranks #561 by composite RQD confidence (43/100, grade D-) and #902 by equity capitalization ($9.2M). Within this direct 5-issuer industry benchmark cohort, MBRX leads on earnings valuation at N/A trailing P/E, while MBRX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. INM currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with MBRX at 43/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MBRX
ACTIVE
Moleculin Biotech Inc. | D- | 43/100 | — | — | -35.0% | -0.29% | $9.2M | Benchmark Subject |
| BFRG Bullfrog AI Holdings Inc. | D- | 40/100 | — | 18.8% | -35.0% | +3.88% | $9.4M | /bfrg-vs-mbrx → |
| INM InMed Pharmaceuticals Inc. | D | 47/100 | — | 34.5% | -35.0% | +1.61% | $8.9M | /inm-vs-mbrx → |
| PTN Palatin Technologies Inc. | D- | 38/100 | — | — | -35.0% | -3.33% | $8.8M | /ptn-vs-mbrx → |
| CMMB Chemomab Therapeutics Ltd. | D- | 38/100 | — | — | -35.0% | -0.91% | $8.8M | /cmmb-vs-mbrx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001659617In its most recent audited fiscal period (FY2025, filed 2025-12-31), Moleculin Biotech Inc. (MBRX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $33.6M, operating cash flow of -$22.7M, and free cash flow of -$22.7M (+4.8% YoY). On the balance sheet, MBRX closed FY2025 with $22.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $33.6M | -$22.7M | -$22.7M | $22.1M | — |
| FY2024 (FY) | 2024-12-31 | $0 | $26.0M | -$23.9M | -$23.9M | $16.9M | — |
| FY2023 (FY) | 2023-12-31 | $0 | $29.8M | -$23.6M | -$23.6M | — | — |
3. MBRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs MBRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Moleculin Biotech Inc. (NASDAQ: MBRX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $8.72 (-0.29% 1D, market cap $9.2M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, MBRX ranks #561 in composite RQD confidence.
How does MBRX compare to BFRG and INM in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MBRX carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BFRG (Bullfrog AI Holdings Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $9.4M) and INM (InMed Pharmaceuticals Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $8.9M). Among the 5-stock peer group, MBRX leads on earnings multiple (N/A) while MBRX leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for MBRX?
Per MBRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001659617), Moleculin Biotech Inc. generated $0 in revenue, $33.6M in net income, and -$22.7M in free cash flow against $22.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is MBRX trading relative to its 50-day, 200-day, and 52-week technical levels?
MBRX last traded at $8.72 (-0.29% on volume of 34,035 shares), positioning the stock -19.56% below its 50-day simple moving average ($10.84) and -78.41% below its 200-day simple moving average ($40.39). Across its 52-week range of $3.22 to $315.00, MBRX sits at the 1.8% percentile with a 14-day RSI of 44.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($7.63 to $9.81).
MBRX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is MBRX stock moving today?
Why MBRX Stock slipped -0.29% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.